Aon plc released findings from a multi-year study of U.S. commercial health claims data on April 30, 2025, highlighting a significant opportunity to reduce healthcare costs and enhance workforce health through comprehensive obesity management programs, including GLP-1 medications. The analysis leveraged Aon's Health Risk Analyzer, evaluating data from over 50 million commercially insured lives. CEO Greg Case emphasized that obesity is an escalating global epidemic, costing the U.S. economy up to $1.72 trillion annually.
Aon's early analysis revealed that GLP-1 medications, when paired with a holistic adherence program, can reduce long-term healthcare expenditures and enhance workforce productivity. As part of its commitment, Aon also launched its own subsidized GLP-1 weight management program for U.S. employees in collaboration with eMed. This program combines affordable access to treatment with virtual support and adherence tools, addressing a costly health challenge.
Lisa Stevens, chief administrative officer of Aon, stated that the firm is proving it is possible to offer access to GLP-1s affordably and with dignity, benefiting both people and the bottom line. Aon works with employers to model the long-term business impact of GLP-1 adoption, providing customized claims analysis and global workforce impact modeling. This initiative sets a new benchmark for the industry in chronic condition prevention and workforce health investment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.